Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Kerr, Jacqueline ^a   Quinti, Isabella ^b   Eibl, Martha ^c   Chapel, Helen ^d   Späth, Peter J ^e   Sewell, W A Carrock ^f   Salama, Abdulgabar ^g   van Schaik, Ivo N ^h   Kuijpers, Taco W ^h   Peter, Hans Hartmut ⁱ  

^a PAUL EHRLICH INSTITUT   (Germany)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Immunologische Tagesklinik   (Austria)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY OF LINCOLN   (United Kingdom)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Dosing; Immunomodulation; IVIG; Replacement therapy; SCIG

Indexed keywords

CD20 ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGAMMAGLOBULINEMIA; AGING; AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HEMOLYTIC ANEMIA; HUMAN; HUMORAL IMMUNE DEFICIENCY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNIZATION; IMMUNOGLOBULIN DEFICIENCY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTIPLE MYELOMA; MYASTHENIA GRAVIS; MYELOMA; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; POLYRADICULONEUROPATHY; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SUBSTITUTION THERAPY; TREATMENT OUTCOME; WISKOTT ALDRICH SYNDROME;

EID: 84919473749     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00629     Document Type: Review

References (193)

1. Robert P. Global plasma demand in 2015. In: Valverde JL, editor. Pharmaceuticals Policy and Law Rare Diseases: Focus on Plasma Related Disorders. Amsterdam: IOS Press (2009). p. 359-67.
2. Khan S, Grimbacher B, Boecking C, Chee R, Allgar V, Holding S, et al. Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy. Drug Metab Lett (2011) 5(2):132-6. doi: 10.2174/187231211795305302
3. Rocchio MA, Hussey AP, Southard RA, Szumita PM. Impact of ideal body weight dosing for all inpatient i.v. immune globulin indications. Am J Health Syst Pharm (2013) 70(9):751-2. doi:10.2146/ajhp110744
4. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol (2012) 32(6):1180-92. doi:10.1007/s10875-012-9720-1
5. Shapiro RS. Why I use subcutaneous immunoglobulin (SCIG). J Clin Immunol (2013) 33(Suppl 2):S95-8. doi:10.1007/s10875-012-9853-2
6. Haddad E, Berger M, Wang EC, Jones CA, Bexon M, Baggish JS. Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency. J Clin Immunol (2012) 32(2):281-9. doi:10.1007/s10875-011-9631-6
7. Fadeyi M, Tran T. Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient. P T (2013) 38(12):768-70.
8. Sewell WA, Kerr J, Behr-Gross ME, Peter HH; Kreuth Ig Working Group. European consensus proposal for immunoglobulin therapies. Eur J Immunol (2014) 44(8):2207-14. doi:10.1002/eji.201444700
9. Bruton O. Agammaglobulinemia. Pediatrics (1952) 9(6):722-8.
10. Cunningham-Rundles C, Siegal FP, Smithwick EM. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med (1984) 101:435-9. doi:10.7326/0003-4819-101-4-435
11. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol (1999) 92:34-48. doi:10.1006/clim.1999.4725
12. Jolles S, Kaveri SV, Orange J. Intravenous immunoglobulins. Current understanding and future directions. Clin Exp Immunol (2009) 1:68-70. doi:10.1111/j.1365-2249.2009.04029.x
13. Chapel H, Cunningham-Rundles C. Update in understanding common variable immuno-deficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol (2009) 145:709-27. doi:10.1111/j.1365-2141.2009.07669.x
14. Ochs HD, Fischer SH, Wedgwood RJ. Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med (1984) 76:78-82. doi:10.1016/0002-9343(84)90324-3
15. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol (2010) 137:21-30. doi:10.1016/j.clim.2010.06.012
16. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol (2012) 169:172-81. doi:10.1111/j.1365-2249.2012.04594.x
17. Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol (2010) 125:1354-60. doi:10.1016/j.jaci.2010.02.040
18. Gathmann B, Mahlaoui N, CEREDIH Network, Gérard L, Oksenhendler E, Warnatz K, et al. . Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol (2014) 134(1):116-26. doi:10.1016/j.jaci.2013.12.1077
19. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol (2011) 31:315-22. doi:10.1007/s10875-011-9511-0
20. Bonagura VR. Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease. Ann Allergy Asthma Immunol (2013) 111(6 Suppl):S10-3. doi:10.1016/j.anai.2013.09.014
21. Landersdorfer CB, Bexon M, Edelman J, Rojavin M, Kirkpatrick CM, Lu J, et al. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgrad Med (2013) 125(6):53-61. doi:10.3810/pgm.2013.11.2712
22. Sidhu J, Rojavin M, Pfister M, Edelman J. Enhancing patient flexibility of subcutaneous immunoglobulin G dosing: pharmacokinetic outcomes of various maintenance and loading regimens in the treatment of primary immunodeficiency. Biol Ther (2014) 4:41-55. doi:10.1007/s13554-014-0018-0
23. Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, Martín-Nalda A, Oliveras M, Martinez-Cutillas J, et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol (2014) 34(8):1015-7. doi:10.1007/s10875-014-0096-2
24. Milito C, Pulvirenti F, Pesce AM, Digiulio MA, Pandolfi F, Visentini M, et al. Adequate patient's outcome achieved with short immunoglobulin replacement intervals in severe antibody deficiencies. J Clin Immunol (2014) 34(7):813-9. doi:10.1007/s10875-014-0081-9
25. Gabriel SE, Normand SL. Getting the methods right-the foundation of patient-centered outcomes research. N Engl J Med (2012) 367:787-90.
26. Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol (2013) 171(2):186-94. doi:10.1111/cei.12002
27. Schroeder HW Jr, Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection (2012) 40:601-11. doi:10.1007/s15010-012-0323-9
28. Mikolajczyk MG, Concepcion NF, Wang T, Frazier D, Golding B, Frasch CE, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol (2004) 11:1158-64.
29. Hagan JB, Fasano MB, Spector S. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol (2010) 30:734-45. doi:10.1007/s10875-010-9423-4
30. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol (2011) 164:2-5. doi:10.1111/j.1365-2249.2011.04387.x
31. Durandy A, Kaveri SV, Kuijpers TW. Intravenous immunoglobulins - understanding properties and mechanisms. Clin Exp Immunol (2009) 158:2-13. doi:10.1111/j.1365-2249.2009.04022.x
32. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol (2011) 127:315-23. doi:10.1016/j.jaci.2010.10.030
33. Wasserman RL, Church JA, Peter HH, Sleasman JW, Melamed I, Stein MR, et al. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency. Eur J Pharmacol (2009) 37(3-4):272-8. doi:10.1016/j.ejps.2009.02.014
34. Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol (2013) 111(1):51-5. doi:10.1016/j.anai.2013.04.015
35. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol (2012) 130(4):951-7. doi:10.1016/j.jaci.2012.06.021
36. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulins for primary and secondary immunodeficiencies: an evidence-based review. Drugs (2013) 73(12):1307-19. doi:10.1007/s40265-013-0094-3
37. Duraisingham SS, Buckland MS, Grigoriadou S, Longhurst HJ. Secondary antibody deficiency. Expert Rev Clin Immunol (2014) 10(5):583-91. doi:10.1586/1744666X.2014.902314
38. Mouthon L, Fermand JP, Gottenberg JE. Management of secondary immune deficiencies: what is the role of immunoglobulins? Curr Opin Allergy Clin Immunol (2013) 13(Suppl 2):S56-67. doi:10.1097/01.all.0000433132.16436.b5
39. Azar AE, Ballas ZK. Evaluation of the adult with suspected immunodeficiency (review). Am J Med (2007) 120(9):764-8. doi:10.1016/j.amjmed.2006.12.013
40. Controlled Clinical Trial Cooperative Group. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia. N Engl J Med (1988) 319(14):902-7. doi:10.1056/NEJM198810063191403
41. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood (1989) 73(2):366-8.
42. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogamma-globulinaemia. Clin Lab Haematol (1995) 17(1):75-80. doi:10.1111/j.1365-2257.1995.tb00322.x
43. Ruuskanen O, Nurkka A, Helminen M, Viljanen MK, Käyhty H, Kainulainen L. Specific antibody deficiency in children with recurrent respiratory infections: a controlled study with follow-up. Clin Exp Immunol (2013) 172(2):238-44. doi:10.1111/cei.12053
44. Sinisalo M, Vilpo J, Itälä M, Väkeväinen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine (2007) 26(1):82-7. doi:10.1016/j.vaccine.2007.10.053
45. Smolej L. Efficacy of pneumococcal vaccination in chronic lymphocytic leukemia: should we rely on surrogate markers? Vaccine (2008) 26(11):1407. doi:10.1016/j.vaccine.2008.01.010
46. Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIg) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica (1996) 81(2):121-6.
47. Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol (1994) 53(2):114-8. doi:10.1111/j.1600-0609.1994.tb01874.x
48. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma. Lancet (1994) 343(8905):1059-63. doi:10.1016/S0140-6736(94)90180-5
49. Karlsson J, Andréasson B, Kondori N, Erman E, Riesbeck K, Hogevik H, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol (2011) 18(6):969-77. doi:10.1128/CVI.00021-11
50. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma (2009) 50(5):764-72. doi:10.1080/10428190902856824
51. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med (1990) 323(11):705-12. doi:10.1056/NEJM199009133231103
52. Cordonnier C, Chevret S, Legrand M, Rafi H, Dhédin N, Lehmann B, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial. Ann Intern Med (2003) 139(1):8-18. doi:10.7326/0003-4819-139-1-200307010-00007
53. Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol (2009) 27(5):770-81. doi:10.1200/JCO.2008.16.8450
54. Sundin M, Nordin K, Jostemyr Y, Winiarski J. Subcutaneous IgG replacement after pediatric SCT. Pediatr Transplant (2012) 16(8):866-71. doi:10.1111/j.1399-3046.2012.01783.x
55. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. N Engl J Med (1991) 325(2):73-80. doi:10.1056/NEJM199107113250201
56. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med (1994) 331(18):1181-7. doi:10.1056/NEJM199411033311802
57. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk (2013) 13(2):106-11. doi:10.1016/j.clml.2012.11.011
58. Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One (2012) 7(5):e37626. doi:10.1371/journal.pone.0037626
59. Thiel J, Salzer U, Hässler F, Effelsberg NM, Hentze C, Sic H, et al. B cell homeostasis is disturbed by immunosuppressive therapies in patients with ANCA-associated vasculitides. Autoimmunity (2013) 46(7):429-38. doi:10.3109/08916934.2013.798652
60. Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What is the impact of hypogamma-globulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant (2013) 13(10):2601-10. doi:10.1111/ajt.12401
61. Rubin RH. Infectious disease complications of renal transplantation (review). Kidney Int (1993) 44(1):221-36. doi:10.1038/ki.1993.234
62. Sarmiento E, Lanio N, Gallego A, Rodriguez-Molina J, Navarro J, Fernandez-Yañez J, et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int Immunopharmacol (2009) 9(6):649-52. doi:10.1016/j.intimp.2008.09.013
63. Carbone J, Sarmiento E, Del Pozo N, Rodriguez-Molina JJ, Navarro J, Fernandez-Yañez J, et al. Restoration of humoral immunity after intravenous immunoglobulin replacement therapy in heart recipients with post-transplant antibody deficiency and severe infections. Clin Transplant (2012) 26(3):E277-83. doi:10.1111/j.1399-0012.2012.01653.x
64. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health (2012) 66(12):1177-81. doi:10.1136/jech-2011-200168
65. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 82(5):299-308. doi:10.1097/01.md.0000091181.93122.55
66. Alarcón GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. VII[correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum (2001) 45(2):191-202. doi:10.1002/1529-0131(200104)45:2<191::AID-ANR173>3.3.CO;2-U
67. Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus (2003) 12(9):672-6. doi:10.1191/0961203303lu452oa
68. Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro. Clin Exp Immunol (1975) 20(2):273-85.
69. Matsuoka H, Okada J, Takahashi T, Matsuoka M, Sato C, Torii S. Immunological study of IgA deficiency during anticonvulsant therapy in epileptic patients. Clin Exp Immunol (1983) 53(2):423-8.
70. Kienzler AK, Rizzi M, Reith M, Nutt SL, Eibel H. Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid. J Allergy Clin Immunol (2013) 131(6):1695-9. doi:10.1016/j.jaci.2013.01.018
71. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet (1981) 1(8232):1228-31. doi:10.1016/S0140-6736(81)92400-4
72. Blanchette V, Imbach P, Andrew M, Adams M, McMillan J, Wang E, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet (1994) 344(8924):703-7. doi:10.1016/S0140-6736(94)92205-5
73. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood (2009) 113(11):2386-93. doi:10.1182/blood-2008-07-162503
74. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 117(16):4190-207. doi:10.1182/blood-2010-08-302984
75. Parodi E, Giordano P, Rivetti E, Giraudo MT, Ansaldi G, Davitto M, et al. Efficacy of combined intravenous immunoglobulins and steroids in children with primary immune thrombocytopenia and persistent bleeding symptoms. Blood Transfus (2014) 12(3):340-5. doi:10.2450/2014.0185-13
76. Alioglu B, Ercan S, Tapci AE, Zengin T, Yazarli E, Dallar Y. A comparison of intravenous immunoglobulin (2 g/kg totally) and single doses of anti-D immunoglobulin at 50 μg/kg, 75 μg/kg in newly diagnosed children with idiopathic thrombocytopenic purpura: Ankara hospital experience. Blood Coagul Fibrinolysis (2013) 24(5):505-9. doi:10.1097/MBC.0b013e32835e5337
77. Lee JH, Lee KS. Efficacy of very low-dose (200 mg/kg/d) with short-term intravenous immunoglobulin G therapy according to individual response of acute immune thrombocytopenic purpura in childhood. Clin Pediatr Hematol Oncol (2006) 13:143-9.
78. Dua V. Very low-dose intravenous immunoglobulin for treatment of immune thrombocytopenic purpura. Indian Pediatr (2013) 50:611.
79. Sruamsiri R, Dilokthornsakul P, Pratoomsoot C, Chaiyakunapruk N. A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding. Pharmacoeconomics (2014) 32(8):801-13. doi:10.1007/s40273-014-0171-9
80. Lee D, Thornton P, Hirst A, Kutikova L, Deuson R, Brereton N. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland. Appl Health Econ Health Policy (2013) 11(5):457-69. doi:10.1007/s40258-013-0044-y
81. Pettigrew M, Garces K, Deuson R, Kassis J, Laroche V. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada. J Med Econ (2013) 16(2):318-26. doi:10.3111/13696998.2012.756400
82. Morimoto Y, Yoshida N, Kawashima N, Matsumoto K, Kato K. Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia. Int J Hematol (2014) 99(5):597-602. doi:10.1007/s12185-014-1551-9
83. Stiakaki E, Perdikogianni C, Thomou C, Markaki EA, Katzilakis N, Tsirigotaki M, et al. Idiopathic thrombocytopenic purpura in childhood: twenty years of experience in a single center. Pediatr Int (2012) 54(4):524-7. doi:10.1111/j.1442-200X.2012.03606.x
84. Peng J, Ma SH, Liu J, Hou Y, Liu XM, Niu T, et al. Association of autoantibody specificity and response to intravenous immunoglobulin G therapy in immune thrombocytopenia: a multicenter cohort study. J Thromb Haemost (2014) 12(4):497-504. doi:10.1111/jth.12524
85. Papagianni A, Economou M, Tragiannidis A, Karatza E, Samarah F, Gombakis N, et al. Fc?RIIa and Fc?RIIIa polymorphisms in childhood primary immune thrombocytopenia: implications for disease pathogenesis and outcome. Blood Coagul Fibrinolysis (2013) 24(1):35-9. doi:10.1097/MBC.0b013e328359bc3b
86. Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M, et al. Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood (2008) 111(3):1029-38. doi:10.1182/blood-2007-03-079913
87. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet (1984) 2(8411):1055-8. doi:10.1016/S0140-6736(84)91504-6
88. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med (1991) 324(23):1633-9. doi:10.1056/NEJM199106063242305
89. Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child (2014) 99(1):74-83. doi:10.1136/archdischild-2012-302841
90. Makowsky R, Wiener HW, Ptacek TS, Silva M, Shendre A, Edberg JC, et al. Fc?R gene copy number in Kawasaki disease and intravenous immunoglobulin treatment response. Pharmacogenet Genomics (2013) 23(9):455-62. doi:10.1097/FPC.0b013e328363686e
91. Fury W, Tremoulet AH, Watson VE, Best BM, Shimizu C, Hamilton J, et al. Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance. Hum Immunol (2010) 71(9):865-73. doi:10.1016/j.humimm.2010.06.008
92. Ogata S, Shimizu C, Franco A, Touma R, Kanegaye JT, Choudhury BP, et al. Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One (2013) 8(12):e81448. doi:10.1371/journal.pone.0081448
93. Lin M-C, Fu Y-C, Jan S-L, Lai M-S. Comparative effectiveness of intravenous immunoglobulin for children with Kawasaki disease: a nationwide cohort study. PLoS One (2013) 8(5):e63399. doi:10.1371/journal.pone.0063399
94. Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matsumoto Y, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr (2000) 137(2):172-6. doi:10.1067/mpd.2000.104815
95. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr (2006) 149(2):237-40. doi:10.1016/j.jpeds.2006.03.050
96. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation (2006) 113(22):2606-12. doi:10.1161/CIRCULATIONAHA.105.592865
97. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart (2013) 99(2):76-82. doi:10.1136/heartjnl-2012-302126
98. Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series. J Rheumatol (2012) 39(4):864-7. doi:10.3899/jrheum.110877
99. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr (2005) 146(5):662-7. doi:10.1016/j.jpeds.2004.12.022
100. Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, et al. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int (2012) 54(1):99-103. doi:10.1111/j.1442-200X.2011.03487.x
101. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics (1979) 63(2):175-9.
102. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association. Pediatrics (2004) 114(6):1708-33. doi:10.1542/peds.2004-2182
103. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med (2007) 356(7):663-75. doi:10.1056/NEJMoa061235
104. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet (2012) 379(9826):1613-20. doi:10.1016/S0140-6736(11)61930-2
105. Son MB, Newburger JW. Management of Kawasaki disease: corticosteroids revisited. Lancet (2012) 379(9826):1571-2. doi:10.1016/S0140-6736(12)60196-2
106. Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr (2011) 158(5):831.e-5.e. doi:10.1016/j.jpeds.2010.10.031
107. van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med (1992) 326(17):1123-9. doi:10.1056/NEJM199204233261705
108. Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology (1996) 46(1):100-3. doi:10.1212/WNL.46.1.100
109. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet (1997) 349(9047):225-30. doi:10.1016/S0140-6736(96)09095-2
110. Asbury AK. New concepts of Guillain-Barré syndrome. J Child Neurol (2000) 15(3):183-91. doi:10.1177/088307380001500308
111. Fokkink WJ, Selman MH, Dortland JR, Durmus B, Kuitwaard K, Huizinga R, et al. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins. J Proteome Res (2014) 13(3):1722-30. doi:10.1021/pr401213z
112. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev (2012) 7:CD002063. doi:10.1002/14651858.CD002063.pub5
113. Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev (2012) 8:CD001446. doi:10.1002/14651858.CD001446.pub4
114. Kornberg AJ, Dalakas MC, Yee WC, Byrne E, Tsai CP, Spaeth P, et al. Expert Consensus Statements on the Use of IVIg in Neurology, Asia Pacifique IVIgAdvisory Board. Canberra, ACT: National Health and Medical Research Council (2004).
115. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC; French Guillain-Barré Syndrome Cooperative Group. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry (2001) 71(2):235-8. doi:10.1136/jnnp.71.2.235
116. Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics (2005) 116(1):8-14. doi:10.1542/peds.2004-1324
117. Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol (2009) 66(5):597-603. doi:10.1002/ana.21737
118. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev (2014) 9:CD002063. doi:10.1002/14651858.CD002063.pub6
119. van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet (2004) 363(9404):192-6. doi:10.1016/S0140-6736(03)15324-X
120. Garssen MP, van Koningsveld R, van Doorn PA, Merkies IS, Scheltens-de Boer M, van Leusden JA, et al. Treatment of Guillain-Barré syndrome with mycophenolate mofetil: a pilot study. J Neurol Neurosurg Psychiatry (2007) 78(9):1012-3. doi:10.1136/jnnp.2006.102731
121. Pritchard J, Gray IA, Idrissova ZR, Lecky BR, Sutton IJ, Swan AV, et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology (2003) 61(9):1282-4. doi:10.1212/01.WNL.0000092019.53628.88
122. Yuki N, Ang CW, Koga M, Jacobs BC, van Doorn PA, Hirata K, et al. Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol (2000) 47(3):314-21. doi:10.1002/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C
123. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (2013) 12:CD001797. doi:10.1002/14651858.CD001797.pub3
124. Eftimov F, van Schaik I. Chronic inflammatory demyelinating polyradiculoneuropathy: update on clinical features, phenotypes and treatment options. Curr Opin Neurol (2013) 26(5):496-502. doi:10.1097/WCO.0b013e328363bfa4
125. Csurhes PA, Sullivan AA, Green K, Pender MP, McCombe PA. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry (2005) 76(10):1431-9. doi:10.1136/jnnp.2004.052282
126. Hughes RA, Allen D, Makowska A, Gregson NA. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst (2006) 11(1):30-46. doi:10.1111/j.1085-9489.2006.00061.x
127. Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst (2008) 13(1):54-63. doi:10.1111/j.1529-8027.2008.00158.x
128. Sanvito L, Makowska A, Gregson N, Nemni R, Hughes RA. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity (2009) 42(8):667-77. doi:10.3109/08916930903140907
129. Schneider-Hohendorf T, Schwab N, Uçeyler N, Göbel K, Sommer C, Wiendl H. CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (2012) 78(6):402-8. doi:10.1212/WNL.0b013e318245d250
130. Van den Berg LH, Mollee I, Wokke JH, Logtenberg T. Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol (1995) 58(1):37-42. doi:10.1016/0165-5728(94)00185-Q
131. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 50(2):195-201. doi:10.1002/ana.1088
132. Nobile-Orazio E, Cocito D, Jann S, Uncini A, Beghi E, Messina P, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol (2012) 11(6):493-502. doi:10.1016/S1474-4422(12)70093-5
133. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol (2010) 67(7):802-7. doi:10.1001/archneurol.2010.105
134. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol (2008) 7(2):136-44. doi:10.1016/S1474-4422(07)70329-0
135. van Schaik IN, Eftimov F, van Doorn PA, Brusse E, van den Berg LH, van der Pol WL, et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol (2010) 9(3):245-53. doi:10.1016/S1474-4422(10)70021-1
136. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (1994) 36(6):838-45. doi:10.1002/ana.410360607
137. Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (2012) 8:CD002062. doi:10.1002/14651858.CD002062.pub2
138. Eftimov F, Liesdek MH, Verhamme C, van Schaik IN; PREDICT Study Group. Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol (2014) 14:72. doi:10.1186/1471-2377-14-72
139. Kuitwaard K, van Doorn PA, Vermeulen M, van den Berg LH, Brusse E, van der Kooi AJ, et al. Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry (2013) 84(8):859-61. doi:10.1136/jnnp-2012-304670
140. Kokubun N, Sada T, Yuki N, Okabe M, Hirata K. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement. Eur Neurol (2013) 70(1-2):65-9. doi:10.1159/000350287
141. Rajabally YA, Seow H, Wilson P. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst (2006) 11(4):325-9. doi:10.1111/j.1529-8027.2006.00105.x
142. Rajabally YA, Wong SL, Kearney DA. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J Neurol (2013) 260(8):2052-6. doi:10.1007/s00415-013-6938-7
143. Broyles R, Rodden L, Riley P, Berger M. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders. Postgrad Med (2013) 125(2):65-72. doi:10.3810/pgm.2013.03.2619
144. Blackhouse G, Gaebel K, Xie F, Campbell K, Assasi N, Tarride JE, et al. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc (2010) 8:14. doi:10.1186/1478-7547-8-14
145. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve (2008) 37(3):406-9. doi:10.1002/mus.20909
146. Markvardsen LH, Debost JC, Harbo T, Sindrup SH, Andersen H, Christiansen I, et al. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol (2013) 20(5):836-42. doi:10.1111/ene.12080
147. Gorson KC, Natarajan N, Ropper AH, Weinstein R. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve (2007) 35(1):66-9. doi:10.1002/mus.20664
148. Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, et al. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology (2010) 74(8):651-7. doi:10.1212/WNL.0b013e3181d1a862
149. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol (2009) 8(2):158-64. doi:10.1016/S1474-4422(08)70299-0
150. Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, Benedetti L, et al. Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy. A nationwide retrospective analysis. Eur J Neurol (2011) 18(12):1417-21. doi:10.1111/j.1468-1331.2011.03495
151. Bedi G, Brown A, Tong T, Sharma KR. Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy. J Neurol Neurosurg Psychiatry (2010) 81(6):634-6. doi:10.1136/jnnp.2009.177576
152. Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol (2010) 257(6):913-9. doi:10.1007/s00415-009-5437-3
153. Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol (1988) 24(1):73-8. doi:10.1002/ana.410240113
154. van der Pol WL, Cats EA, van den Berg LH. Intravenous immunoglobulin treatment in multifocal motor neuropathy. J Clin Immunol (2010) 30(Suppl 1):S79-83. doi:10.1007/s10875-010-9408-3
155. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. Cochrane Database Syst Rev (2005) 18(2):CD004429. doi:10.1002/14651858.CD004429.pub2
156. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst (2011) 16(2):92-7. doi:10.1111/j.1529-8027.2011.00330.x
157. Braine ME, Woodall A. A comparison between intravenous and subcutaneous immunogobulin. Br J Nurs (2012) 21(8):S21-2. doi:10.12968/bjon.2012.21.Sup5.S21
158. Vlam L, van der Pol WL, Cats EA, Straver DC, Piepers S, Franssen H, et al. Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol (2011) 8(1):48-58. doi:10.1038/nrneurol.2011.175
159. Nobile-Orazio E, Giannotta C, Musset L, Messina P, Léger JM. Sensitivity and predictive value of anti-GM1/galactocerebroside IgM antibodies in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry (2014) 85(7):754-8. doi:10.1136/jnnp-2013-305755
160. Jinka M, Chaudhry V. Treatment of multifocal motor neuropathy. Curr Treat Options Neurol (2014) 16(2):269. doi:10.1007/s11940-013-0269-y
161. Umapathi T, Hughes RA, Nobile-Orazio E, Léger JM. Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev (2012) 4:CD003217. doi:10.1002/14651858.CD003217.pub4
162. Vlam L, Cats EA, Willemse E, Franssen H, Medic J, Piepers S, et al. Pharmacokinetics of intravenous immunoglobulin in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry (2014) 85(10):1145-8. doi:10.1136/jnnp-2013-306227
163. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst (2009) 14(2):93-100. doi:10.1111/j.1529-8027.2009.00218.x
164. Piepers S, Van den Berg-Vos R, Van der Pol WL, Franssen H, Wokke J, Van den Berg L. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial. Brain (2007) 130(Pt 8):2004-10. doi:10.1093/brain/awm144
165. Chaudhry V, Cornblath DR. An open-label trial of rituximab (Rituxan®) in multifocal motor neuropathy. J Peripher Nerv Syst (2010) 15(3):196-201. doi:10.1111/j.1529-8027.2010.00270.x
166. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest (2006) 116(11):2843-54. doi:10.1172/JCI29894
167. Gajdos P, Outin H, Elkharrat D, Brunel D, de Rohan-Chabot P, Raphael JC, et al. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet (1984) 1(8373):406-7. doi:10.1016/S0140-6736(84)90469-0
168. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol (2005) 62(11):1689-93. doi:10.1001/archneur.62.11.1689
169. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev (2012) 12:CD002277. doi:10.1002/14651858.CD002277.pub4
170. Espinoza JP, Caradeux J, Norwitz ER, Illanes SE. Fetal and neonatal alloimmune thrombocytopenia. Rev Obstet Gynecol (2013) 6(1):e15-21.
171. Tiller H, Kamphuis MM, Flodmark O, Papadogiannakis N, David AL, Sainio S, et al. Fetal intracranial haemorrhages caused by fetal and neonatoal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open (2013) 3(3):e002490. doi:10.1136/bmjopen-2012-002490
172. Bussel JB, Berkowitz RL, McFarland JG, Lynch L, Chitkara U. Antenatal treatment of neonatal alloimmune thrombocytopenia. N Engl J Med (1988) 319:1374-8. doi:10.1056/NEJM198811243192103
173. Murphy MF, Bussel JB. Advances in the management of alloimmune thrombocytopenia. Br J Haematol (2006) 136:366-78. doi:10.1111/j.1365-2141.2006.06418.x
174. Kamphuis MM, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia. Prenat Diagn (2011) 31:712-9. doi:10.1002/pd.2779
175. Cook TJ, Qiu CC, Dickinson JE. Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin. Aust N Z J Obstet Gynaecol (2012) 52(4):321-6. doi:10.1111/j.1479-828X.2012.01438.x
176. Van Der Lugt NM, Kamphuis MM, Paridaans NP, Figee A, Oepkes D, Walther FJ, et al. Neonatal outcome in alloimmune thrombocytopenia after maternal treatment with intravenous immunoglobulin. Blood Transfus (2014) 19:1-6. doi:10.2450/2014.0309-13
177. Bertrand G, Kaplan C. How do we treat fetal and neonatal alloimmune thrombocytopenia? Transfusion (2014) 54(7):1698-703. doi:10.1111/trf.12671
178. Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia (review). Cochrane Database Syst Rev (2011) 5:CD004226. doi:10.1002/14651858.CD004226.pub3
179. Chen P, Li C, Lang S, Zhu G, Reheman A, Spring CM, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood (2010) 116(18):3660-8. doi:10.1182/blood-2010-05-284919
180. Tiller H, Killie MK, Chen P, Eksteen M, Husebekk A, Skogen B, et al. Toward a prophylaxis against fetal an neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion (2012) 52:1446-57. doi:10.1111/j.1537-2995.2011.03480.x
181. Ghevaert C, Herbert N, Hawkins L, Grehan N, Cookson P, Garner SF, et al. Recombinant HPA-1a antibody therapy for treatment of fetomaternal alloimmune thrombocytopenia: proof of principle in human volunteers. Blood (2013) 122(3):313-20. doi:10.1182/blood-2013-02-481887
182. Bakchoul T, Greinacher A, Sachs UJ, Krautwurst A, Renz H, Hab H, et al. Inhibition of HPA-1a alloantibody-mediated platelet destruction by a deglycosylated anti-HPA-1a monoclonal antibody in mice: toward targeted treatment of fetal-alloimmune thrombocytopenia. Blood (2013) 122(3):321-7. doi:10.1182/blood-2012-11-468561
183. Kjeldsen-Kragh J, Ni H, Skogen B. Towards a prophylactic treatment of HPA-related foetal and neonatal alloimmune thrombocytopenia. Curr Opin Hematol (2012) 19(6):469-74. doi:10.1097/MOH.0b013e328358f86c
184. Branch DW, Porter FT, Paidas MJ, Belfort MA, Gonik B. Obstetric use of intravenous immuno-globulin: successes, failures, and promises. Allergy Clin Immunol (2001) 108(4 Suppl):S133-8. doi:10.1067/mai.2001.117821
185. Wong KS, Connan K, Rowlands S, Kornmann LH, Svoia HF. Antenatal immunoglobulin for fetal red blood cell alloimmunization. Cochrane Database Syst Rev (2013) 5:CD008267. doi:10.1002/14651858.CD008267.pub2
186. Dalakas MC. Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations. J Clin Immunol (2014) 34(Suppl 1):S120-6. doi:10.1007/s10875-014-0024-5
187. Enk A, Fierlbeck G, French L, Girolomino G, Hertl M, Jolles S, et al. Update of the guideline on the use of high-dose intravenous immunoglobulin in dermatology. Eur Dermatol Forum (2011). doi:10.1684/ejd.2008.0580
188. Danieli MG, Gambini S, Pettinari L, Logullo F, Veronesi G, Gabrielli A. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev (2014) 13(10):1048-54. doi:10.1016/j.autrev.2014.08.023
189. Rider LG, Katz JD, Jones OY. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am (2013) 39(4):877-904. doi:10.1016/j.rdc.2013.06.001
190. Seidling V, Hoffmann JHO, Enk AH, Eva NH. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm Venereol (2013) 93:346-9. doi:10.2340/00015555-1471
191. Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. Int J Dermatol (2014). doi:10.1111/ijd.12423
192. Jolles S, Bernatowska E, de Gracia J, Borte M, Cristea V, Peter HH, et al. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol (2011) 141(1):90-102. doi:10.1016/j.clim.2011.06.002
193. von Geldern G, Mc Pharlin T, Becker K. Immune mediated diseases and immunmodulation in the neurocritical care unit. Neurotherapeutics (2012) 9:99-123. doi:10.1007/s13311-011-0096-3